The initiation of coverage by TD Cowen with a Market Perform rating suggests that the analyst believes Sana Biotechnology's stock will perform in line with the average return of the analyst's industry coverage universe over the next 12 months. This could potentially influence investors' decisions, but it's not necessarily indicative of a significant price movement in the short term.